Cisplatin Disposition and Kidney Injury

Running, not enrolling · Phase 3

Conditions studied: Nephrotoxicity

In brief

This study is being done to determine 1) whether drugs to treat cisplatin-related nausea can influence harm to the kidneys, 2) whether cisplatin levels in the body can influence the risk of harm to the kidneys, and 3) whether a person's genetic make-up can increase or decrease the likelihood of kidney injury due to cisplatin therapy.

Key facts

Study ID: NCT03817970
Run by: University of Colorado, Denver
People needed: 72
Starts: 2019-11-15
Expected to finish: 2027-12-31
Last updated by the study team: 2025-08-11

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Male or female patient prescribed cisplatin at a dose of >25mg/m\^2
Age 18-80 years
Hemoglobin >/=9 g/dl
No consumption of grapefruit juice or alcohol within 7 days
No history of alcohol consumption of >14 drinks/week
No history of organ transplantation or kidney dialysis
Willingness to comply with study
Not pregnant or lactating
No changes in chronic medications within 2 weeks
Estimated glomerular filtration rate (eGFR) > 60 ml/min\^2
Normal liver function (ALT and AST <2x ULN)

You may not qualify if…

Diagnosis of kidney cancer
Previous exposure to platinum-based chemotherapy with the exception of one previous dose as part of the current course
Herbal supplement use beyond marijuana
Exposure to other known nephrotoxins (including contrast agents) within the previous 2 weeks
Severe gastrointestinal disease with fluid losses
Diagnosis of a rapidly progressive glomerulonephritis
Allergy or contraindication to 5-HT3 Antagonists

Where it is running

UCHealth-Metro Denver — Denver, Colorado, United States
Memorial Sloan Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.